Biomarkers in Parkinson's disease.
Biomarkers are objectively measured characteristics that are indicators of normal biological processes, pathogenic processes, or responses to therapeutic interventions. To date, clinical assessment remains the gold standard in the diagnosis of Parkinson's disease (PD) and clinical rating scales are well established as the gold standard for tracking progression of PD. Researchers have identified numerous potential biomarkers that may aid in the differential diagnosis of PD and/or tracking disease progression. Clinical, genetic, blood and cerebrospinal fluid (proteomics, transcriptomics, metabolomics), and neuroimaging biomarkers may provide useful tools in the diagnosis of PD and in measuring disease progression and response to therapies. Some potential biomarkers are inexpensive and do not require much technical expertise, whereas others are expensive or require specialized equipment and technical skills. Many potential biomarkers in PD show great promise; however, they need to be assessed for their sensitivity and specificity over time in large and varied samples of patients with and without PD.
Morgan
John C
JC
Department of Neurology, Medical College of Georgia, Augusta, GA 30912, USA.
Mehta
Shyamal H
SH
Sethi
Kapil D
KD
D015415:Biomarkers / Q000378:metabolism*; D003937:Diagnosis, Differential; D003952:Diagnostic Imaging / Q000379:methods; D018450:Disease Progression; D020869:Gene Expression Profiling / Q000379:methods; D006801:Humans; D010300:Parkinson Disease / Q000175:diagnosis* / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology
D015415:Biomarkers
Exp Neurol. 2008 Oct;213(2):315-25
18625222
Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):955-60
17215369
Hum Mol Genet. 2009 Apr 15;18(R1):R48-59
19297401
Lancet Neurol. 2010 Feb;9(2):149-58
20061183
Mov Disord. 2009 Mar 15;24(4):551-6
19086085
Mov Disord. 2006 Jul;21(7):916-23
16547944
Acta Neurol Scand. 1995 Apr;91(4):247-50
7625148
Am J Clin Pathol. 2008 Apr;129(4):526-9
18343778
Mov Disord. 2009 Oct 30;24(14):2081-90
19691116
Neurology. 2005 Mar 22;64(6):1081-3
15781836
Sleep Med. 2010 Apr;11(4):361-5
20223708
Neurology. 1992 Apr;42(4):726-32
1565224
Clin Pharmacol Ther. 2001 Mar;69(3):89-95
11240971
Neuroimaging Clin N Am. 2010 Feb;20(1):29-55
19959017
Neurology. 1999 Sep 22;53(5):1026-31
10496262
Neurology. 2001 Aug 14;57(3):456-62
11502913
N Engl J Med. 2004 Dec 9;351(24):2498-508
15590952
FASEB J. 2006 Mar;20(3):419-25
16507759
Neurology. 2005 Jan 25;64(2):208-15
15668415
Arch Neurol. 2004 Aug;61(8):1224-9
15313838
Neurology. 1995 Jan;45(1):182-4
7824114
Qual Life Res. 1995 Jun;4(3):241-8
7613534
Mov Disord. 2009;24 Suppl 2:S732-41
19877202
Neurology. 1967 May;17(5):427-42
6067254
Arch Neurol. 2009 Dec;66(12):1460-8
19822770
Mov Disord. 2000 May;15(3):467-473
28470732
Curr Opin Neurol. 2004 Aug;17(4):417-23
15247536
N Engl J Med. 2009 Oct 22;361(17):1651-61
19846850
Mov Disord. 2003 Jul;18(7):738-50
12815652
Arch Neurol. 2008 Jun;65(6):716-23
18413464
Ann Neurol. 2004 Aug;56(2):173-81
15293269
J Neurol. 2007 Jan;254(1):84-90
17508142
J Proteomics. 2009 Nov 2;73(1):10-29
19632367
J Biomed Sci. 2009 Jul 13;16:63
19594911
Neurology. 2003 Jan 14;60(1):74-7
12525721
Age Ageing. 1999 Mar;28(2):99-102
10350403
Neurology. 2009 Apr 21;72(16):1378-84
19129507
J Neurol Sci. 1999 Nov 30;170(2):90-5
10561523
Mov Disord. 2005 Mar;20(3):383-5
15486999
Neurodegeneration. 1995 Mar;4(1):93-7
7600189
Exp Neurol. 2008 Aug;212(2):307-13
18511044
J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1749-52
15548497
Curr Neurol Neurosci Rep. 2008 Jul;8(4):297-303
18590613
N Engl J Med. 2009 Feb 19;360(8):753-64
19228618
Brain. 2008 Feb;131(Pt 2):389-96
18222993
Neurology. 2010 Jan 19;74(3):239-44
20083800
Neurology. 2009 Apr 14;72(15):1296-300
19109537
Neurology. 1999 Oct 22;53(7):1488-94
10534256
Mov Disord. 2008 Sep 15;23(12):1653-7
18618666
Clin Infect Dis. 1997 May;24(5):764-74
9142767
Neurology. 2001 Oct 23;57(8):1497-9
11673599
J Neural Transm (Vienna). 2006 Oct;113(10):1463-8
16604308
N Engl J Med. 1992 Jul 23;327(4):227-33
1377359